EDAP TMS (EDAP) 2025 Conference June 05, 2025 04:20 PM ET Speaker0 Okay. Alright. Good afternoon. My name is Michael Sarcone. I'm an analyst on the US Medical Supplies and Devices team, this is day two of the Jefferies twenty twenty five New York Healthcare Conference. This is a session with EDAP Focal One. And with us from the company, we've got Ryan Rhodes, CEO Ken Moback, CFO and John Francis who heads the IR function. Ryan Rhodes is going to give a presentation, some prepared commentary and then we'll o ...

Format: Corporate update Date/Time: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ET for registered conference attendees Location: Virtual Registration Link: Click Here About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next- generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS ...

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the first pa ...

Core Insights - Bio-Path Holdings, Inc. is a clinical-stage biotechnology company focused on RNA interference therapeutics using its DNAbilize® platform [1] - The lead candidate, prexigebersen (BP1001), is in Phase 2 trials for acute myeloid leukemia (AML) and shows potential for FDA approval [7] - Bio-Path is advancing its pipeline with multiple candidates targeting various cancers and metabolic diseases [1][7] Company Overview - Bio-Path Holdings, Inc. is based in Bellaire, Texas and specializes in RNAi therapeutics [1] - The company employs a proprietary liposomal delivery system to enhance drug stability and cellular uptake while reducing toxicity [1] Pipeline Development - Prexigebersen (BP1001) targets the Grb2 protein and is currently in Phase 2 trials for AML [1] - A modified version, BP1001-A, is in Phase 1/1b trials for solid tumors and has shown early efficacy [7] - Another candidate, BP1002, targets the Bcl-2 protein for blood cancers and solid tumors [1] - Bio-Path is preparing an IND application for BP1003, a STAT3 inhibitor for pancreatic cancer [1]

Entrada Therapeutics (TRDA) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Hang on one second. Nope. Which button? Is it the green? Well, they're all green. Oh, the big green. Okay. Before I begin, I just need to remind you that during the presentation, I'll be making forward looking statements. So please refer to our public SEC disclosures. We're progressing '25 through '25 in a very quick and efficient manner. And there's a lot of momentum that's building for the company as I speak today. So by the en ...

Relay Therapeutics (RLAY) 2025 Conference June 04, 2025 08:45 AM ET Speaker0 Okay. Well, let's get started. Hey everyone, thanks so much for attending the Jefferies Healthcare Conference. Really appreciate you guys being here so bright and early. I'm Amy Lee, I'm a biotech analyst and I have the pleasure of welcoming the Relay Therapeutics management team. We have Sanjeev Patel, the Chief Executive Officer Don Bergstrom, the President of R and D and Pete Raymer, the Chief Corporate Development Officer. So R ...

Core Insights - Revive Therapeutics Ltd. is advancing its next-generation lyophilized formulation of Bucillamine, developed in collaboration with the University of Waterloo, to address significant unmet medical needs and create shareholder value [1][6] Strategic Development - The company is targeting public health emergencies, including pandemic influenza and emerging infectious diseases, while pursuing FDA incentives such as Emergency Use Authorization and Orphan Drug Designation to facilitate rapid market entry [2][6] Product Potential - Bucillamine has FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation, awarded in 2022, indicating its promise and potential for accelerated development [3] - Research suggests Bucillamine may enhance solid tumor treatments in cancer, with interest from a prominent clinical researcher to investigate its anti-tumor effects in patients with advanced solid tumors [3] Partnerships and Research - Revive is collaborating with Defence R&D Canada on a study evaluating Bucillamine for nerve agent exposure, with positive results expected by June 2025, potentially leading to human clinical trials and subsequent FDA and Health Canada approvals [4] - The potential applications of Bucillamine also include traumatic brain injury and viral infections, expanding its market potential [4] Ongoing Developments - The company is in the process of settling a previously announced arbitration award with LTS Lohmann Therapie-System AG [5]

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed under "Events ...

Continued focus on patients, customers, and innovation helping to drive new advances in clinical research for life science companiesNEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand, has seen significant momentum and reaffirmed its vision to progress the life sciences industry forward, securing new enterprise agreements with several large customers, a strengthened industry partnership in central nervous system (CNS), a strengthened presence in digital therapeutics, and expanded ...

Core Insights - Telix Pharmaceuticals Limited is hosting an Investor Day on June 11, 2025, in New York City, focusing on growth opportunities in precision medicine and therapeutic radiopharmaceuticals [1][4] Company Overview - Telix is a biopharmaceutical company dedicated to developing and commercializing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, with operations in the U.S., Brazil, Canada, Europe, and Japan [4] - The company is addressing significant unmet medical needs in oncology and rare diseases through its clinical and commercial stage products [4] Event Details - The Investor Day will feature key opinion leaders discussing the clinical utility and opportunities for Telix's theranostic candidates [2] - In-person attendance is available for institutional investors and analysts, with advance registration required [3] Key Opinion Leaders - Dr. Oliver Sartor, an expert in prostate cancer, will discuss TLX591, having published over 500 peer-reviewed articles and led pivotal Phase 3 studies [7] - Dr. John de Groot, a neuro-oncology expert, will present on TLX101, with over 200 peer-reviewed publications and significant involvement in clinical studies [7] - Dr. Joseph Osborne, specializing in renal cancer imaging, will cover TLX250-CDx, focusing on advancing molecular imaging [7]